About this trial
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based interpretation system can accurately diagnose inherited metabolic disorders in newborns undergoing routine screening. The main questions it aims to answer are:
What is the sensitivity and specificity of the AI system compared to standard manual interpretation? Does the AI system reduce variability in screening results? Researchers will compare the AI interpretation results with those from standard manual review by trained laboratory staff to assess diagnostic performance.
Participants will:
Have their routine newborn screening blood samples analyzed using both the AI system and standard manual interpretation Be followed according to national newborn screening guidelines if either method indicates a positive result
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Newborns who underwent routine newborn screening for inherited metabolic disorders at the Zhejiang Provincial Newborn Screening Center between May 2025 and December 2027
Blood samples collected between 2 and 28 days of age
Availability of complete newborn screening test data and essential clinical information
Disqualifiers
Missing, incomplete, or poor-quality screening data
Duplicate samples from the same newborn
Trial design
Single group
Treatments tested in this trial
Artificial intelligence-based interpretation system for newborn genetic metabolic disease screening
Diagnostic testThis intervention is a deep learning-based software algorithm designed specifically for the interpretation of tandem mass spectrometry (MS/MS) data from routine newborn screening in Chinese neonates. It integrates clinical covariates-including gestational age, birth weight, and blood collection time-to perform multiple-of-the-median (MOM) normalization and simultaneously evaluates 42 inherited metabolic disorders. Unlike existing AI tools developed for older-generation screening panels (e.g., those covering only 29 analytes), this system is trained and validated on over 300,000 real-world Chinese newborn samples, making it the first AI diagnostic tool tailored to China's current expanded newborn screening program.
Treatment groups
Trial outcomes
Primary outcomes
Sensitivity of the AI interpretation system for detecting inherited metabolic disorders
Specificity of the AI interpretation system for detecting inherited metabolic disorders
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: